Telaprevir‑based triple therapy following partial splenic arterial embolization for chronic hepatitis C with thrombocytopenia can reduce carcinogenesis and improve hepatic function reserve

Ishikawa,Toru; Abe,Satoshi; Kojima,Yuichi; Horigome,Ryoko; Sano,Tomoe; Iwanaga,Akito; Seki,Keiichi; Honma,Terasu; Yoshida,Toshiaki

doi:10.3892/etm.2015.2674

Telaprevir‑based triple therapy following partial splenic arterial embolization for chronic hepatitis C with thrombocytopenia can reduce carcinogenesis and improve hepatic function reserve

Authors:
- Toru Ishikawa
- Satoshi Abe
- Yuichi Kojima
- Ryoko Horigome
- Tomoe Sano
- Akito Iwanaga
- Keiichi Seki
- Terasu Honma
- Toshiaki Yoshida
View Affiliations

Affiliations: Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata 950‑1104, Japan
Published online on: August 7, 2015 https://doi.org/10.3892/etm.2015.2674
Pages: 1334-1338
Copyright: © Ishikawa et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thrombocytopenia in patients with chronic hepatitis C negatively impacts interferon (IFN)‑based treatment. The aim of this study was to evaluate the efficacy and safety of telaprevir (TVR)‑based triple therapy including IFN for patients who have undergone partial splenic arterial embolization (PSE). Ten patients with thrombocytopenia who were infected with hepatitis C virus (HCV) genotype 1b received 12 weeks of TVR in combination with 24 weeks of pegylated interferon (PEG‑IFN)α2b and ribavirin following PSE. A sustained virological response (SVR) was seen in 9 of the 10 patients who could be assessed. Early relapse was seen in 1 patient who had the IL‑28B minor allele and a null response to pretreatment. The α‑fetoprotein levels of the patients decreased from 17.94±7.30 ng/ml prior to PSE to 4.33±2.41 ng/ml at 6 months after triple therapy (P=0.08). Furthermore, serum albumin levels improved significantly from 3.68±0.49 g/dl pre‑PSE to 4.13±0.34 g/dl at 12 months after triple therapy (P=0.043). PSE contributed to the treatment success of triple therapy, particularly for patients who were either treatment‑naïve, had a history of relapse or the IL28B major allele. This strategy can reduce carcinogenesis and improve hepatic function reserve.

View Figures

View References

1	Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, et al: Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 132:103–112. 2007. View Article : Google Scholar : PubMed/NCBI
2	Shimizu H, Takatsuka K, Nakano H, Tenjin T, Fujikawa T, Yoshida A, Yoshimatsu E, Matsui K and Iwabuchi S: Long-term evaluation of partial splenic embolization followed by interferon therapy in patients with hepatitis C virus (HCV) cirrhosis and thrombocytopenia. Intern Med. 53:925–931. 2014. View Article : Google Scholar : PubMed/NCBI
3	Hanafiah M, Shahizon AM, Low SF and Shahrina MH: Severe thrombocytopenia due to hypersplenism treated with partial splenic embolisation. BMJ Case Rep 2013. pii: bcr201301016363. 2011.
4	McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J and Muir AJ: PROVE1 Study Team: Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 360:1827–1838. 2009. View Article : Google Scholar : PubMed/NCBI
5	Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, et al: Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 360:1839–1850. 2009. View Article : Google Scholar : PubMed/NCBI
6	McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, et al: Telaprevir for previously treated chronic HCV infection. N Engl J Med. 362:1292–1303. 2010. View Article : Google Scholar : PubMed/NCBI
7	Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, et al: Telaprevir for retreatment of HCV infection. N Engl J Med. 364:2417–2428. 2011. View Article : Google Scholar : PubMed/NCBI
8	Ikeda N, Imanishi H, Aizawa N, Tanaka H, Iwata Y, Enomoto H, Saito M, Iijima H, Iimuro Y, Fujimoto J, et al: Nationwide survey in Japan regarding splenectomy/partial splenic embolization for interferon treatment targeting hepatitis C virus-related chronic liver disease in patients with low platelet count. Hepatol Res. 44:829–836. 2014. View Article : Google Scholar : PubMed/NCBI
9	Shimizu H, Takatsuka K, Yoshida A, Yoshimatsu E, Matsui K and Iwabuchi S: Partial splenic embolization reverses insulin resistance in patients with liver cirrhosis. Intern Med. 48:747–751. 2009. View Article : Google Scholar : PubMed/NCBI
10	Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, et al: Kyushu University Liver Disease Study (KULDS) Group: Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy. J Hepatol. 59:667–674. 2013. View Article : Google Scholar : PubMed/NCBI
11	Aster RH: Pooling of platelets in the spleen: Role in the pathogenesis of ‘hypersplenic’ thrombocytopenia. J Clin Invest. 45:645–57. 1966. View Article : Google Scholar : PubMed/NCBI
12	Aoki Y, Hirai K and Tanikawa K: Mechanism of thrombocytopenia in liver cirrhosis: Kinetics of indium-111 tropolone labeled platelets. Eur J Nucl Med. 20:123–129. 1993. View Article : Google Scholar : PubMed/NCBI
13	Nagamine T, Ohtuka T, Takehara K, Arai T, Takagi H and Mori M: Thrombocytopenia associated with hepatitis C viral infection. J Hepatol. 24:135–140. 1996. View Article : Google Scholar : PubMed/NCBI
14	Ishikawa T, Ichida T, Matsuda Y, Sugitani S, Sugiyama M, Kato T, Miyazaki H and Asakura H: Reduced expression of thrombopoietin is involved in thrombocytopenia in human and rat liver cirrhosis. J Gastroenterol Hepatol. 13:907–913. 1998. View Article : Google Scholar : PubMed/NCBI
15	Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, Weksler B and Esteban R: Thrombocytopenia associated with chronic liver disease. J Hepatol. 48:1000–1007. 2008. View Article : Google Scholar : PubMed/NCBI
16	Linton RR, Jones CM and Volwiler W: Portal hypertension; the treatment by splenectomy and splenorenal anastomosis with preservation of the kidney. Surg Clin North Am. 27:1162–1170. 1947.PubMed/NCBI
17	Goldstone J: Splenectomy for massive splenomegaly. Am J Surg. 135:385–388. 1978. View Article : Google Scholar : PubMed/NCBI
18	Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV and Facklam RR: Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA. 270:1826–1831. 1993. View Article : Google Scholar : PubMed/NCBI
19	Waghorn DJ and Mayon-White RT: A study of 42 episodes of overwhelming post-splenectomy infection: Is current guidance for asplenic individuals being followed? J Infect. 35:289–294. 1997. View Article : Google Scholar : PubMed/NCBI
20	Okabayashi T and Hanazaki K: Overwhelming postsplenectomy infection syndrome in adults - A clinically preventable disease. World J Gastroenterol. 14:176–179. 2008. View Article : Google Scholar : PubMed/NCBI
21	Maddison FE: Embolic therapy of hypersplenism. Invest Radiol. 8:280–281. 1973. View Article : Google Scholar
22	Spigos DG, Jonasson O, Mozes M and Capek V: Partial splenic embolization in the treatment of hypersplenism. Am J Roentgenol. 132:777–782. 1979. View Article : Google Scholar
23	Yoshida H, Mamada Y, Taniai N and Tajiri T: Partial splenic embolization. Hepatol Res. 38:225–233. 2008. View Article : Google Scholar : PubMed/NCBI
24	Ishikawa T, Kubota T, Horigome R, Kimura N, Honda H, Iwanaga A, Seki K, Honma T and Yoshida T: Concurrent partial splenic embolization with transcatheter arterial chemoembolization for hepatocellular carcinoma can maintain hepatic functional reserve. Hepatol Res. 44:1056–1061. 2014. View Article : Google Scholar : PubMed/NCBI
25	Amin MA, el-Gendy MM, Dawoud IE, Shoma A, Negm AM and Amer TA: Partial splenic embolization versus splenectomy for the management of hypersplenism in cirrhotic patients. World J Surg. 33:1702–1710. 2009. View Article : Google Scholar : PubMed/NCBI
26	Hayashi H, Beppu T, Masuda T, Mizumoto T, Takahashi M, Ishiko T, Takamori H, Kanemitsu K, Hirota M and Baba H: Predictive factors for platelet increase after partial splenic embolization in liver cirrhosis patients. J Gastroenterol Hepatol. 22:1638–1642. 2007. View Article : Google Scholar : PubMed/NCBI
27	Miyake Y, Ando M, Kaji E, Toyokawa T, Nakatsu M and Hirohata M: Partial splenic embolization prior to combination therapy of interferon and ribavirin in chronic hepatitis C patients with thrombocytopenia. Hepatol Res. 38:980–986. 2008. View Article : Google Scholar : PubMed/NCBI
28	Tahara H, Takagi H, Sato K, Shimada Y, Tojima H, Hirokawa T, Ohyama T, Horiuchi K, Naganuma A, Arai H, et al: A retrospective cohort study of partial splenic embolization for antiviral therapy in chronic hepatitis C with thrombocytopenia. J Gastroenterol. 46:1010–1019. 2011. View Article : Google Scholar : PubMed/NCBI